Clinical trialNCT05432804RecruitingPhase 1/PHASE2Interventional

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

SponsorNational Cancer Institute (NCI)Enrollment97Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozolomide) in treating patients with glioblastoma that has come back (recurrent). Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Giving selinexor in combination with usual chemotherapy (temozolomide) may shrink or stabilize the tumor better than the usual chemotherapy with temozolomide alone in patients with recurrent glioblastoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jana L Portnow
City of Hope Comprehensive Cancer Center LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

36 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
Alyx B. Porter Umphrey
Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Jana L. Portnow
Recruiting
Uc San Diego Moores Cancer Center
La Jolla, California, United States
David E. Piccioni
Recruiting
Keck Medicine of Usc Koreatown
Los Angeles, California, United States
Suspended
Los Angeles General Medical Center
Los Angeles, California, United States
Suspended
Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Suspended
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Orwa Aboud
Recruiting
Uchealth University of Colorado Hospital
Aurora, Colorado, United States
Denise M. Damek
Recruiting
Um Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, United States
Macarena I. De La Fuente
Recruiting
Um Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, United States
Macarena I. De La Fuente
Recruiting
Mayo Clinic in Florida
Jacksonville, Florida, United States
Sani H. Kizilbash
Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
Macarena I. De La Fuente
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Patrick T. Grogan
Recruiting
Emory University Hospital Midtown
Atlanta, Georgia, United States
Kimberly Hoang
Recruiting
Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
Kimberly Hoang
Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Lauren Singer
Recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois, United States
Lauren Singer
Recruiting
University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
John L. Villano
Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Sani H. Kizilbash
Recruiting
Cooperman Barnabas Medical Center
Livingston, New Jersey, United States
Andrew B. Brown
Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Andrew B. Brown
Recruiting
Rutgers New Jersey Medical School
Newark, New Jersey, United States
Suspended
Roswell Park Cancer Institute
Buffalo, New York, United States
Active, not recruiting
Laura and Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
Jose R. McFaline Figueroa
Recruiting
Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center
New York, New York, United States
Active, not recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Roy E. Strowd
Recruiting
University of Cincinnati Cancer Center-Uc Medical Center
Cincinnati, Ohio, United States
Lalanthica V. Yogendran
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Pierre Giglio
Recruiting
University of Cincinnati Cancer Center-West Chester
West Chester, Ohio, United States
Lalanthica V. Yogendran
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
James D. Battiste
Recruiting
Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Megan Mantica
Recruiting
Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Active, not recruiting
University of Virginia Cancer Center
Charlottesville, Virginia, United States
Active, not recruiting
Vcu Massey Comprehensive Cancer Center
Richmond, Virginia, United States
Active, not recruiting
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, United States
Ankush Bhatia
Recruiting
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Ankush Bhatia
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Placebo AdministrationSelinexor →Temozolomide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Mar 2023
Primary completion: 30 Jun 2027
Completion: 30 Jun 2027
Last update posted: 13 Aug 2026
Registered enrollment: 97
Registry id: NCT05432804

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.